Literature DB >> 21393202

Impetigo in a population over 8.5 years: incidence, fusidic acid resistance and molecular characteristics.

Sverre Rørtveit1, Dag Harald Skutlaberg, Nina Langeland, Guri Rortveit.   

Abstract

OBJECTIVES: From around year 2000, impetigo caused by fusidic acid-resistant Staphylococcus aureus was observed in countries of Northern Europe. The bacteria were found to represent a clone, the epidemic European fusidic acid-resistant impetigo clone (EEFIC). This study reports longitudinal data on the incidence and bacteriology of impetigo in a Norwegian island community during the years 2001-09. PATIENTS AND METHODS: All encounters with general practitioners regarding impetigo were registered. Bacterial swabs were taken in a high percentage of cases. Annual incidence was calculated. Phenotypic characteristics of the bacteria were determined for the whole period, and in 2008 and 2009 we also performed PFGE and spa typing.
RESULTS: Outbreaks of impetigo were observed in 2002, 2003 and 2004, but since then the incidence decreased greatly. S. aureus was cultured from the impetigo site in the majority of cases. The proportion of S. aureus isolates resistant to fusidic acid decreased from 80% in 2002-04 to 45% in 2008-09. For 28 S. aureus isolates analysed by molecular methods in 2008-09, we found that nearly all cases of fusidic acid resistance were due to the presence of the EEFIC.
CONCLUSIONS: S. aureus resistance to fusidic acid in relation to impetigo is now less frequent in this population than at the start of the century. At present, most S. aureus bacteria resistant to fusidic acid in impetigo belong to the EEFIC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21393202     DOI: 10.1093/jac/dkr102

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections.

Authors:  Anastassios Doudoulakakis; Iris Spiliopoulou; Nikolaos Spyridis; Nikolaos Giormezis; John Kopsidas; Maria Militsopoulou; Evangelia Lebessi; Maria Tsolia
Journal:  J Clin Microbiol       Date:  2017-06-07       Impact factor: 5.948

2.  NVC-422 topical gel for the treatment of impetigo.

Authors:  Susan M Iovino; Kenneth D Krantz; Daisy M Blanco; Josefina A Fernández; Naomi Ocampo; Azar Najafi; Bahram Memarzadeh; Chris Celeri; Dmitri Debabov; Behzad Khosrovi; Mark Anderson
Journal:  Int J Clin Exp Pathol       Date:  2011-07-23

3.  Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.

Authors:  Antonio Torrelo; Ramon Grimalt; Xavier Masramon; Núria Albareda López; Ilonka Zsolt
Journal:  Dermatology       Date:  2020-01-20       Impact factor: 5.366

4.  The use of typing methods and infection prevention measures to control a bullous impetigo outbreak on a neonatal ward.

Authors:  Maike Koningstein; Leon Groen; Kathelijn Geraats-Peters; Suzanne Lutgens; Ariene Rietveld; Petr Jira; Jan Kluytmans; Sabine C de Greeff; Mirjam Hermans; Peter M Schneeberger
Journal:  Antimicrob Resist Infect Control       Date:  2012-11-20       Impact factor: 4.887

5.  The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.

Authors:  Mehdi Goudarzi; Bahareh Hajikhani; Sareh Kakavandi; Sana Amini; Samira Zamani; Alex van Belkum; Hossein Goudarzi; Masoud Dadashi
Journal:  Antimicrob Resist Infect Control       Date:  2021-05-01       Impact factor: 6.454

6.  Use of primary care data for detecting impetigo trends, United kingdom, 1995-2010.

Authors:  Laura J Shallcross; Irene Petersen; Joe Rosenthal; Anne M Johnson; Nick Freemantle; Andrew C Hayward
Journal:  Emerg Infect Dis       Date:  2013-10       Impact factor: 6.883

Review 7.  Impetigo - review.

Authors:  Luciana Baptista Pereira
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

8.  The decline of the impetigo epidemic caused by the epidemic European fusidic acid-resistant impetigo clone: an 11.5-year population-based incidence study from a community in Western Norway.

Authors:  Sverre Rørtveit; Dag Harald Skutlaberg; Nina Langeland; Guri Rortveit
Journal:  Scand J Infect Dis       Date:  2014-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.